12:00 AM
Mar 02, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ESBA105: Phase IIa started

ESBATech began an open-label, German Phase IIa trial to evaluate topical ESBA105 in 25 patients.

ESBATech AG, Zurich, Switzerland

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >